

IN THE CLAIMS:

Claims 1-14 (canceled)

Claim 15. (Currently Amended) An immunogenic composition comprising: a CS3 peptide ~~wherein when said peptide is minimized, the minimized peptide binds to a Class II-MHC receptor DR1 inhibiting the binding of HA residues 306-318,~~

said peptide selected from ~~the group consisting of~~

CS3 ~~having~~ consisting of the amino acid sequence of SKNGTVTWAHETNNSA, Seq.

ID No: 3;

CS6A7 having the amino acid sequence of ILYQIVDEKGKKK, Seq. ID No: 6;

CS6A6 having the amino acid sequence of DEYGLGRLVNTAD, Seq. ID No: 5;

CS6E5 having the amino acid sequence of GTYAGHLTVSFYS, Seq. ID No: 12;

CS6E4 having the amino acid sequence of GEYPNSGYSSGTY, Seq. ID No: 11;

CS6E3 having the amino acid sequence of TSYTFSAIYTGGE, Seq. ID No: 10; and

CS6E2 having the amino acid sequence of QLYTVEMTIPAGV, Seq. ID No: 9.

Claim 16. (canceled)

Claim 17. (canceled)

Claim 18. (withdrawn) A method of eliciting an immune response in an animal comprising administering said animal with the immunogenic composition according to claim 15.

Claim 19. (canceled)

Claim 20. (canceled)

Claim 21. (previously presented) The immunogenic composition of claim 15, wherein said composition is immunogenic against pathogenic microorganisms and neoplasms.

Claim 22. (previously presented) The immunogenic composition of claim 15, wherein said composition is immunogenic against Enterotoxogenic E. Coli.

Claim 23. (canceled)

Claim 24. (canceled)

Claim 25. (previously presented)The immunogenic composition of claim 15, wherein said composition is combined with an immunologically acceptable carrier.

Claim 26. (previously presented) The immunogenic composition of claim 25, wherein said encapsulation microspheres comprise biodegradable bio-compatible poly (DL-lactide-co-glycolide) as a bulk matrix.

Claims 27-37 (cancelled)

Claim 38-47 (cancelled)

Claim 48. (previously presented) The immunogenic composition of claim 15 wherein said peptide is a synthetic peptide.

Claim 49. (previously presented) The immunogenic composition of claim 25 wherein said immunologically acceptable carrier comprises encapsulating microspheres.

Claim 50. **(new)** The immunogenic composition of claim 15, wherein when said peptide is minimized, the minimized peptide binds to a Class II MHC receptor DR1 inhibiting the binding of HA residues 306-318.

Claim 51. **(new)** An immunogenic composition comprising: a CS3 peptide with an amino acid sequence of SKNGTVTWAHETNNSA, Seq. ID No: 3, wherein said peptide is not a whole CS3 protein.

Claim **52. (new)** The immunogenic composition of claim 51, wherein when said peptide is minimized, the minimized peptide binds to a Class II MHC receptor DR1 inhibiting the binding of HA residues 306-318.

Claim 53. (New) An immunogenic composition comprising: a synthetic CS3 peptide that has been modified from the natural CS3 peptide sequence to bind to a Class II MHC receptor DR1.

Claim 54. (New) An immunogenic composition comprising a CS3 peptide fragment that binds to a Class II MHC receptor DR1.